BEIJING and HANGZHOU, China, Oct. 7, 2024
/PRNewswire/ -- The 32nd United European
Gastroenterology Week (UEG Week 2024) will take place in
Vienna, Austria, from October 12 to 15, 2024. UEG Week is the largest
gastroenterology conference in Europe and one of the leading meetings
worldwide. It brings together gastroenterology experts, physicians,
researchers, and industry representatives from around the globe to
share the latest research advances, clinical practices, and
treatment solutions. Sciwind Biosciences Co., Ltd. will present the
latest research progress on an oral, long-acting glucagon-like
peptide 2 (GLP-2) for the treatment of short bowel syndrome in an
oral presentation.
Details of the oral presentation are as follows:
Title: Discovery of an Oral, Long-Acting Glucagon-Like
Peptide 2 as Best-in-Class Treatment for Short Bowel Syndrome
(#OP160)
Presenter: Haixia Zou, PhD
Session Name: Short bowel syndrome
Session Time/Date: 08:30 am - 09:30
am, Oct 15, 2024,
Session Room: Lehar 1
Presentation Number: OP160
About GLP-2 and Short Bowel Syndrome
GLP-2 is a peptide hormone secreted by the intestine and belongs
to the glucagon family. It is primarily secreted by L cells in the
intestine after meals. Its main functions include promoting
intestinal growth, repair, and nutrient absorption, as well as
regulating gastrointestinal function. Short bowel syndrome is a
malabsorption syndrome caused by a significant reduction in the
length of the small intestine. The main characteristic of this
condition is the body's inability to absorb nutrients, fluids, and
electrolytes properly due to the partial or total loss of small
intestinal function. This condition is often caused by surgical
resection, congenital defects, or intestinal disease. It severely
impacts patients' quality of life, leading to malnutrition, weight
loss, chronic diarrhea, and other complications. Currently,
injectable GLP-2 analogs are approved for the treatment of short
bowel syndrome, and the development of an oral, long-acting GLP-2
molecule would greatly improve patient compliance and
convenience.
About Sciwind Biosciences
Sciwind Biosciences is a clinical stage biopharmaceutical
company focusing on discovering and developing innovative therapies
to treat metabolic disease. Its product pipeline consists of
potentially first-in-class and best-in-class drug candidates,
including the long-acting GLP-1 peptide analog XW003 (Phase 3),
oral GLP-1 peptide analog XW004 (Phase 1), an oral small molecule
GLP-1 receptor agonist XW014 (Phase 1), and novel amylin analogs
(preclinical). Sciwind has developed multiple proprietary
technologies, including oral peptide and inhaled protein
therapeutic delivery platforms and identified a series of drug
candidates based on these core platform technologies. For more
information, visit www.sciwindbio.com.
View original
content:https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-oral-presentation-on-oral-glp-2-research-progress-at-the-32nd-united-european-gastroenterology-week-ueg-week-2024-302261785.html
SOURCE Hangzhou Sciwind Biosciences Co., Ltd.